Tocilizumab for the treatment of COVID-19

Mario Fernández-Ruiz; Francisco López-Medrano; José María Aguado

doi:10.1080/14712598.2021.1880563

Tocilizumab for the treatment of COVID-19

Expert Opin Biol Ther. 2021 Apr;21(4):431-434. doi: 10.1080/14712598.2021.1880563. Epub 2021 Jan 27.

Authors

Mario Fernández-Ruiz¹, Francisco López-Medrano^{1

2}, José María Aguado^{1

2}

Affiliations

¹ Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (Imas12), Madrid, Spain.
² Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.

No abstract available

Keywords: COVID-19; immunomodulatory therapy; observational study; tocilizumab; trial.

Publication types

Editorial

Grants and funding

This work was supported by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation (COVID-19 Research Call COV20/00181) — co‐financed by European Development Regional Fund ‘A way to achieve Europe’. M.F.R. holds a research contract ‘Miguel Servet’ (CP18/00073) from the ISCIII, Spanish Ministry of Science and Innovation.